arca cap analogue Search Results


anti-reverse cap analogue (arca) dinucleotide cap 0 analogue (m 7,3'-o gpppg)  (BioNTech)
90
BioNTech anti-reverse cap analogue (arca) dinucleotide cap 0 analogue (m 7,3'-o gpppg)
Mono- and dual labelling of IVT RNA. ( A ) Scheme of the process: NTPs mix in the presence or absence of <t>initiating</t> <t>dinucleotide</t> <t>(ARCA,</t> N 3 -AG or N 3 -m 7 GpppG) are incubated with gene-coding DNA template in presence of T7 RNA polymerase. After isolation from IVT mixture, RNA products are subjected to 3′ labelling (top) or simultaneous 5′+3′ dual labelling (bottom). ( B ) Representative HPLC chromatograms of crude labelling products of Cy3 3′ labelling (top) or Cy5/Cy3 5′+3′ dual labelling (bottom) performed on 35, 276 and 993 nucleotide-long RNAs (ppp-RNA 35 , N 3 -RNA 35 , N 3 -m 7 GRNA 276 and N 3 -m 7 GRNA gluc ). ( C ) Absorbance and fluorescence HPLC profiles of crude dual labelling product Cy5-m 7 GRNA gluc -Cy3 with designated retention times of collected fractions (right) and agarose electrophoresis of concentrated HPLC fractions (left); ( D ) HPLC chromatogram of crude 3′-biotinylated mRNA N 3 -m 7 GRNA gluc -Biot (right) and electrophoretic mobility shift assay (EMSA) of crude and HPLC-isolated products of 3′ biotinylation (left).
Anti Reverse Cap Analogue (Arca) Dinucleotide Cap 0 Analogue (M 7,3' O Gpppg), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/arca+cap+analogue/anti+reverse+cap+analogue++arca++dinucleotide+cap+0+analogue++m+7+3++o+gpppg+/pmc08755103-170-7-45
Average 90 stars, based on 1 article reviews
anti-reverse cap analogue (arca) dinucleotide cap 0 analogue (m 7,3'-o gpppg) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
new ‘anti-reverse’ 5′-mrna dinucleotide cap analogues (arca)  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies new ‘anti-reverse’ 5′-mrna dinucleotide cap analogues (arca)
Mono- and dual labelling of IVT RNA. ( A ) Scheme of the process: NTPs mix in the presence or absence of <t>initiating</t> <t>dinucleotide</t> <t>(ARCA,</t> N 3 -AG or N 3 -m 7 GpppG) are incubated with gene-coding DNA template in presence of T7 RNA polymerase. After isolation from IVT mixture, RNA products are subjected to 3′ labelling (top) or simultaneous 5′+3′ dual labelling (bottom). ( B ) Representative HPLC chromatograms of crude labelling products of Cy3 3′ labelling (top) or Cy5/Cy3 5′+3′ dual labelling (bottom) performed on 35, 276 and 993 nucleotide-long RNAs (ppp-RNA 35 , N 3 -RNA 35 , N 3 -m 7 GRNA 276 and N 3 -m 7 GRNA gluc ). ( C ) Absorbance and fluorescence HPLC profiles of crude dual labelling product Cy5-m 7 GRNA gluc -Cy3 with designated retention times of collected fractions (right) and agarose electrophoresis of concentrated HPLC fractions (left); ( D ) HPLC chromatogram of crude 3′-biotinylated mRNA N 3 -m 7 GRNA gluc -Biot (right) and electrophoretic mobility shift assay (EMSA) of crude and HPLC-isolated products of 3′ biotinylation (left).
New ‘Anti Reverse’ 5′ Mrna Dinucleotide Cap Analogues (Arca), supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/arca+cap+analogue/new++anti+reverse%E2%80%99+5++mrna+dinucleotide+cap+analogues++arca+/us07074596-213-7-19
Average 90 stars, based on 1 article reviews
new ‘anti-reverse’ 5′-mrna dinucleotide cap analogues (arca) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
antireverse cap 0 analogue (arca)  (ApexBio)
90
ApexBio antireverse cap 0 analogue (arca)
Mono- and dual labelling of IVT RNA. ( A ) Scheme of the process: NTPs mix in the presence or absence of <t>initiating</t> <t>dinucleotide</t> <t>(ARCA,</t> N 3 -AG or N 3 -m 7 GpppG) are incubated with gene-coding DNA template in presence of T7 RNA polymerase. After isolation from IVT mixture, RNA products are subjected to 3′ labelling (top) or simultaneous 5′+3′ dual labelling (bottom). ( B ) Representative HPLC chromatograms of crude labelling products of Cy3 3′ labelling (top) or Cy5/Cy3 5′+3′ dual labelling (bottom) performed on 35, 276 and 993 nucleotide-long RNAs (ppp-RNA 35 , N 3 -RNA 35 , N 3 -m 7 GRNA 276 and N 3 -m 7 GRNA gluc ). ( C ) Absorbance and fluorescence HPLC profiles of crude dual labelling product Cy5-m 7 GRNA gluc -Cy3 with designated retention times of collected fractions (right) and agarose electrophoresis of concentrated HPLC fractions (left); ( D ) HPLC chromatogram of crude 3′-biotinylated mRNA N 3 -m 7 GRNA gluc -Biot (right) and electrophoretic mobility shift assay (EMSA) of crude and HPLC-isolated products of 3′ biotinylation (left).
Antireverse Cap 0 Analogue (Arca), supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/arca+cap+analogue/antireverse+cap+0+analogue++arca+/pm38227975-142-12-17
Average 90 stars, based on 1 article reviews
antireverse cap 0 analogue (arca) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Mono- and dual labelling of IVT RNA. ( A ) Scheme of the process: NTPs mix in the presence or absence of initiating dinucleotide (ARCA, N 3 -AG or N 3 -m 7 GpppG) are incubated with gene-coding DNA template in presence of T7 RNA polymerase. After isolation from IVT mixture, RNA products are subjected to 3′ labelling (top) or simultaneous 5′+3′ dual labelling (bottom). ( B ) Representative HPLC chromatograms of crude labelling products of Cy3 3′ labelling (top) or Cy5/Cy3 5′+3′ dual labelling (bottom) performed on 35, 276 and 993 nucleotide-long RNAs (ppp-RNA 35 , N 3 -RNA 35 , N 3 -m 7 GRNA 276 and N 3 -m 7 GRNA gluc ). ( C ) Absorbance and fluorescence HPLC profiles of crude dual labelling product Cy5-m 7 GRNA gluc -Cy3 with designated retention times of collected fractions (right) and agarose electrophoresis of concentrated HPLC fractions (left); ( D ) HPLC chromatogram of crude 3′-biotinylated mRNA N 3 -m 7 GRNA gluc -Biot (right) and electrophoretic mobility shift assay (EMSA) of crude and HPLC-isolated products of 3′ biotinylation (left).

Journal: Nucleic Acids Research

Article Title: Ethylenediamine derivatives efficiently react with oxidized RNA 3′ ends providing access to mono and dually labelled RNA probes for enzymatic assays and in vivo translation

doi: 10.1093/nar/gkab867

Figure Lengend Snippet: Mono- and dual labelling of IVT RNA. ( A ) Scheme of the process: NTPs mix in the presence or absence of initiating dinucleotide (ARCA, N 3 -AG or N 3 -m 7 GpppG) are incubated with gene-coding DNA template in presence of T7 RNA polymerase. After isolation from IVT mixture, RNA products are subjected to 3′ labelling (top) or simultaneous 5′+3′ dual labelling (bottom). ( B ) Representative HPLC chromatograms of crude labelling products of Cy3 3′ labelling (top) or Cy5/Cy3 5′+3′ dual labelling (bottom) performed on 35, 276 and 993 nucleotide-long RNAs (ppp-RNA 35 , N 3 -RNA 35 , N 3 -m 7 GRNA 276 and N 3 -m 7 GRNA gluc ). ( C ) Absorbance and fluorescence HPLC profiles of crude dual labelling product Cy5-m 7 GRNA gluc -Cy3 with designated retention times of collected fractions (right) and agarose electrophoresis of concentrated HPLC fractions (left); ( D ) HPLC chromatogram of crude 3′-biotinylated mRNA N 3 -m 7 GRNA gluc -Biot (right) and electrophoretic mobility shift assay (EMSA) of crude and HPLC-isolated products of 3′ biotinylation (left).

Article Snippet: Examples of such caps are commercially available anti-reverse cap analogue (ARCA), which is as dinucleotide cap 0 analogue (m 7,3 ′ - O GpppG) ( , ), or a trinucleotide cap 1 analogue (m 7,3′-O Gppp m2′-O ApG), which is used in the production of BioNTech/Pfizer mRNA COVID-19 vaccine ( ).

Techniques: Incubation, Isolation, Fluorescence, Electrophoresis, Electrophoretic Mobility Shift Assay